Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | ESRRG | P62508 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | FPR2 | P25090 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.65 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.64 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.64 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.64 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30758593 | 0.98 | KMT2A (0.70) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL7705937 | 0.94 | ALDH1A1 (0.76) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL15618832 | 0.92 | RAB9A (0.77) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL28489579 | 0.91 | NPC1 (0.72) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL16562279 | 0.89 | ALDH1A1 (0.69) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL9313096 | 0.87 | MAPT (0.71) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL6570625 | 0.87 | RAB9A (0.70) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL1569166 | 0.85 | KMT2A (0.72) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL16562294 | 0.85 | KMT2A (0.70) | KMT2ARAB9AMAPTALDH1A1NPC1 | |
| SCHEMBL3241452 | 0.85 | RAB9A (0.68) | KMT2ARAB9AMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367700-B2 | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-2358681-A1 | SUBSTITUTED 4-(1,2,3,4-TETRAHYDROISOCHINOLIN-2-YL)-4-OXO-BUTYRIC ACID AMIDE AS KCNQ2/2 MODULATORS | Grünenthal GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010075973-A1 | SUBSTITUTED 4-(1,2,3,4-TETRAHYDROISOCHINOLIN-2-YL)-4-OXO-BUTYRIC ACID AMIDE AS KCNQ2/2 MODULATORS | Grünenthal GmbH (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-1730103-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | KCNAB1, KCNQ2, KCNQ1 | KMT2A 330/4885RAB9A 2908/4885MAPT 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.